PubMed:27716209 JSONTXT

{"project":"luoyt2021_800_3","denotations":[{"id":"T1","span":{"begin":11,"end":23},"obj":"CI"},{"id":"T2","span":{"begin":1853,"end":1865},"obj":"CI"},{"id":"T3","span":{"begin":825,"end":837},"obj":"CI"},{"id":"T4","span":{"begin":558,"end":570},"obj":"CI"},{"id":"T5","span":{"begin":278,"end":290},"obj":"CI"},{"id":"T6","span":{"begin":147,"end":159},"obj":"CI"},{"id":"T7","span":{"begin":1795,"end":1802},"obj":"CI"},{"id":"T8","span":{"begin":878,"end":885},"obj":"CI"},{"id":"T9","span":{"begin":433,"end":440},"obj":"CI"}],"text":"Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial.\nBACKGROUND: Whether testosterone treatment has benefits on body composition over and above caloric restriction in men is unknown. We hypothesised that testosterone treatment augments diet-induced loss of fat mass and prevents loss of muscle mass.\nMETHODS: We conducted a randomised double-blind, parallel, placebo controlled trial at a tertiary referral centre. A total of 100 obese men (body mass index ≥ 30 kg/m(2)) with a total testosterone level of or below 12 nmol/L and a median age of 53 years (interquartile range 47-60) receiving 10 weeks of a very low energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of 10-weekly intramuscular testosterone undecanoate (n = 49, cases) or matching placebo (n = 51, controls). The main outcome measures were the between-group difference in fat and lean mass by dual-energy X-ray absorptiometry, and visceral fat area (computed tomography).\nRESULTS: A total of 82 men completed the study. At study end, compared to controls, cases had greater reductions in fat mass, with a mean adjusted between-group difference (MAD) of -2.9 kg (-5.7 to -0.2; P = 0.04), and in visceral fat (MAD -2678 mm(2); -5180 to -176; P = 0.04). Although both groups lost the same lean mass following VLED (cases -3.9 kg (-5.3 to -2.6); controls -4.8 kg (-6.2 to -3.5), P = 0.36), cases regained lean mass (3.3 kg (1.9 to 4.7), P \u003c 0.001) during weight maintenance, in contrast to controls (0.8 kg (-0.7 to 2.3), P = 0.29) so that, at study end, cases had an attenuated reduction in lean mass compared to controls (MAD 3.4 kg (1.3 to 5.5), P = 0.002).\nCONCLUSIONS: While dieting men receiving placebo lost both fat and lean mass, the weight loss with testosterone treatment was almost exclusively due to loss of body fat.\nTRIAL REGISTRATION: clinicaltrials.gov, identifier NCT01616732 , registration date: June 8, 2012."}

{"project":"Linmchun_800_3","denotations":[{"id":"T1","span":{"begin":11,"end":23},"obj":"CI"},{"id":"T2","span":{"begin":147,"end":159},"obj":"CI"},{"id":"T3","span":{"begin":278,"end":290},"obj":"CI"},{"id":"T4","span":{"begin":558,"end":570},"obj":"CI"},{"id":"T5","span":{"begin":825,"end":837},"obj":"CI"},{"id":"T6","span":{"begin":878,"end":885},"obj":"CI"},{"id":"T7","span":{"begin":1853,"end":1865},"obj":"CI"},{"id":"T8","span":{"begin":1795,"end":1802},"obj":"CI"},{"id":"T9","span":{"begin":433,"end":440},"obj":"CI"}],"text":"Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial.\nBACKGROUND: Whether testosterone treatment has benefits on body composition over and above caloric restriction in men is unknown. We hypothesised that testosterone treatment augments diet-induced loss of fat mass and prevents loss of muscle mass.\nMETHODS: We conducted a randomised double-blind, parallel, placebo controlled trial at a tertiary referral centre. A total of 100 obese men (body mass index ≥ 30 kg/m(2)) with a total testosterone level of or below 12 nmol/L and a median age of 53 years (interquartile range 47-60) receiving 10 weeks of a very low energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of 10-weekly intramuscular testosterone undecanoate (n = 49, cases) or matching placebo (n = 51, controls). The main outcome measures were the between-group difference in fat and lean mass by dual-energy X-ray absorptiometry, and visceral fat area (computed tomography).\nRESULTS: A total of 82 men completed the study. At study end, compared to controls, cases had greater reductions in fat mass, with a mean adjusted between-group difference (MAD) of -2.9 kg (-5.7 to -0.2; P = 0.04), and in visceral fat (MAD -2678 mm(2); -5180 to -176; P = 0.04). Although both groups lost the same lean mass following VLED (cases -3.9 kg (-5.3 to -2.6); controls -4.8 kg (-6.2 to -3.5), P = 0.36), cases regained lean mass (3.3 kg (1.9 to 4.7), P \u003c 0.001) during weight maintenance, in contrast to controls (0.8 kg (-0.7 to 2.3), P = 0.29) so that, at study end, cases had an attenuated reduction in lean mass compared to controls (MAD 3.4 kg (1.3 to 5.5), P = 0.002).\nCONCLUSIONS: While dieting men receiving placebo lost both fat and lean mass, the weight loss with testosterone treatment was almost exclusively due to loss of body fat.\nTRIAL REGISTRATION: clinicaltrials.gov, identifier NCT01616732 , registration date: June 8, 2012."}